In April 2025, Blue Cross Blue Shield of Massachusetts (BCBSMA), the states largest insurer, announced that it would end coverage of GLP-1 medications for obesity treatment beginning in January 2026, a move that will significantly restrict access for Boston residents who depend on these treatments
However, the findings provide encouraging evidence that injectable semaglutide may emerge as a promising therapeutic option for women with PMOS seeking improvements in both metabolic and reproductive health.
When your body has enough of this compound, it can effectively manage oxidative stress
Commonly prescribed GLP-1 medications include: Semaglutide (Wegovy, Ozempic) , widely used for both weight loss and metabolic health due to its strong appetite-suppressing effect Liraglutide (Saxenda) , an earlier GLP-1 option that requires daily dosing rather than weekly injections Exenatide , a less commonly used medication today that helped establish early GLP-1 therapy All of these medications act on a single hormone pathway by activating the GLP-1 receptor